CARL ZEISS MEDITEC ADR 1

Here is an emphasis on the importance of diversification in US-based investment portfolios to mitigate risks and enhance returns. The recommendation is to focus on sectors with strong growth potential, such as technology, defense, and media. These picks have solid financial performance and favorable market conditions as key factors for the positive outlook. » Mehr auf seekingalpha.com

Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's strategic R&D investments and growing recurring revenue position it well for future recovery and growth. The company's valuation has dipped, but I believe it offers a compelling long-term upside, with potential annualized returns of 15-30%. » Mehr auf seekingalpha.com

Carl Zeiss Meditec AG (OTCPK:CZMWF) Q3 2024 Results Conference Call August 6, 2024 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - CEO & Chairman of Management Board Justus Wehmer - CFO & Member of the Management Board Conference Call Participants Oliver Reinberg - Kepler Cheuvreux Graham Doyle - UBS Dylan van Haaften - Stifel Sam England - Berenberg Falko Friedrichs - Deutsche Bank Jack Reynolds-Clark - RBC Capital Markets Davide Marchesin - Equita Oliver Metzger - ODDO BHF Alexander Galitsa - Hauck Anchal Verma - JPMorgan Richard Felton - Goldman Sachs Operator Good morning, ladies and gentlemen, and welcome to the Carl Zeiss Meditec AG Analyst Conference 9M 2023/'24 Results. [Operator Instructions]. » Mehr auf seekingalpha.com